"The ophthalmologists and retina specialists at Vitreous Retina Macula Consultants of New York are internationally known leaders in diagnosing and treating retinal diseases. VRMNY retina doctors have trained and taught at some of the world's finest and most respected academic institutions. The physicians who comprise the best retina specialists in New York are experts in vitrectomy surgery and hold academic appointments at Lenox Hill Hospital, New York University, and the New York Eye and Ear Infirmary. Our ophthalmologists in New York City specialize in treating all medical and surgical retinal conditions, emphasizing macular degeneration and diabetic retinopathy, the two leading causes of retinal vision loss."

During the past decade, Vitreous Retina Macula Consultants of New York conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 7 clinical trials were completed, i.e. on average, 53.8% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Vitreous Retina Macula Consultants of New York" #1 sponsor was "Vitreous -Retina- Macula Consultants of New York" with 9 trials, followed by "Apellis Pharmaceuticals, Inc." with 4 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored, "Topcon Medical Systems, Inc." with 3 trials sponsored and "Boston Image Reading Center" with 3 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Vitreous Retina Macula Consultants of New York" #1 collaborator was "Genentech, Inc." with 4 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator, "MEDARVA Foundation" with 1 trials as a collaborator and "QLT Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Vitreous Retina Macula Consultants of New York" are "Geographic Atrophy" (8 trials), "Age Related Macular Degeneration" (2 trials), "Choroidal Neovascularization" (2 trials), "Dry Macular Degeneration" (2 trials) and "Macular Degeneration" (2 trials). Many other conditions were trialed in "Vitreous Retina Macula Consultants of New York" in a lesser frequency.

Most popular intervention types in "Vitreous Retina Macula Consultants of New York" are "Drug" (18 trials), "Other" (6 trials), "Device" (4 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (3 trials), "APL-2" (2 trials), "Aflibercept" (2 trials), "Lampalizumab" (2 trials) and "SS-OCT imaging" (2 trials). Other intervention names were less common.

The vast majority of trials in "Vitreous Retina Macula Consultants of New York" are 26 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Vitreous Retina Macula Consultants of New York". undefined are not yet recruiting, 1 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Vitreous Retina Macula Consultants of New York, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Vitreous Retina Macula Consultants of New York, 6 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".